StockData
Schrodinger, Inc. logo

Schrodinger, Inc. (SDGR) stock

SDGRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3076% above fair value
$30.85−0.67 (-2.13%)

Close on Nov 12, 2026Market cap $2.31BP/E –Yield –

Earnings

Schrodinger's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 24, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$64.50M
+18.8% on a year earlier
Adjusted EPS, Q3 FY2026
-$0.50
-$0.57 a year earlier
Latest guidance
Issued
Nov 4, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Schrodinger's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 24, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$64.50M+18.8%-$0.50–Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026during market hours$58.90M+7.5%$0.08–Release
Q1 FY2026ended Mar 31, 2026May 5, 2026during market hours$58.60M-1.7%-$0.81–Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026during market hours$87.20M-1.2%––Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025during market hours$54.30M+53.8%-$0.45-$0.57Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025during market hours$54.80M+15.9%-$0.59-$0.65Release
Q1 FY2025ended Mar 31, 2025May 7, 2025during market hours$59.60M+62.8%-$0.82-$0.64Release
Q4 FY2024ended Dec 31, 2024Feb 26, 2025during market hours$88.30M+19.2%–-$0.24Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open$35.30M-17.1%-$0.52-$0.87Release
Q2 FY2024ended Jun 30, 2024Jul 31, 2024during market hours$47.30M+34.4%-$0.74-$0.66Release
Q1 FY2024ended Mar 31, 2024May 1, 2024during market hours$36.60M-43.5%-$0.76-$0.86Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Schrodinger's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Drug discovery revenueFY2026$75.00M – $85.00M–NewNov 4, 2026
Drug discovery revenueFY2026$65.00M – $75.00M$55.00M – $65.00MRaisedAug 5, 2026
ACVFY2026$222.00M – $232.00M–NewNov 4, 2026
ACVFY2026$218.00M – $228.00M$218.00M – $228.00MReaffirmedAug 5, 2026
ACV growthFY2026+10% – +15%+10% – +15%ReaffirmedAug 5, 2026
Software ACVFY2026$218.00M – $228.00M–NewFeb 25, 2026

Guidance vs results

The last range Schrodinger gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$49.00M – $52.00M$255.90MΣ4QAbove range
FY2025Revenue growth+8% – +13%+23.33%Σ4QAbove range
Q3 FY2025Revenue$36.00M – $40.00M$54.30MAbove range
Q2 FY2025Revenue$38.00M – $42.00M$54.80MAbove range
Q1 FY2025Revenue$44.00M – $48.00M$59.60MAbove range
Q3 FY2024Revenue$32.00M – $34.00M$35.30MAbove range
Q2 FY2024Revenue$31.00M – $33.00M$47.30MAbove range
Q1 FY2024Revenue$33.00M – $35.00M$36.60MAbove range
Q3 FY2023Revenue$27.00M – $31.00M$42.60MAbove range
Q2 FY2023Revenue$27.00M – $31.00M$35.20MAbove range
Q1 FY2023Revenue$31.00M – $35.00M$64.80MAbove range
Q4 FY2022Revenue$34.00M – $39.00M$56.80MAbove range

Guidance history

Every forecast Schrodinger put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026ACVFY2026$222.00M – $232.00MNew
Nov 4, 2026Drug discovery revenueFY2026$75.00M – $85.00MNew
Aug 5, 2026ACV growthFY2026+10% – +15%Reaffirmed
Aug 5, 2026ACVFY2026$218.00M – $228.00MReaffirmed
Aug 5, 2026ACV, excluding contribution ACVQ3 FY2026$41.00M – $45.00MNew
Aug 5, 2026Drug discovery revenueFY2026$65.00M – $75.00MRaised
May 5, 2026ACV growthFY2026+10% – +15%New
May 5, 2026ACVFY2026$218.00M – $228.00MReaffirmed
May 5, 2026ACVQ2 FY2026$19.00M – $23.00MNew
May 5, 2026Drug discovery revenueFY2026$55.00M – $65.00MReaffirmed
Feb 25, 2026Software ACVFY2026$218.00M – $228.00MNew
Feb 25, 2026software ACVQ1 FY2026$24.00M – $28.00MNew
Feb 25, 2026Drug discovery revenueFY2026$55.00M – $65.00MNew
Nov 5, 2025Software gross marginFY202573% – 75%New
Nov 5, 2025Software revenue growthFY2025+8% – +13%New
Nov 5, 2025Drug discovery revenueFY2025$49.00M – $52.00MNew
Aug 6, 2025Software gross marginFY202574% – 75%New
Aug 6, 2025software revenueQ3 FY2025$36.00M – $40.00MNew
Aug 6, 2025Software revenue growthFY2025+10% – +15%New
Aug 6, 2025Drug discovery revenueFY2025$45.00M – $50.00MReaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Schrodinger filed with the SEC as exhibits to Form 8-K or 6-K

  1. Schrödinger Reports Third Quarter 2026 Financial Results
    Results
  2. Schrödinger Reports Second Quarter 2026 Financial Results
    Results
  3. Schrödinger Reports First Quarter 2026 Financial Results
    Results
  4. Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results
    Results
  5. Schrödinger Reports Third Quarter 2025 Financial Results
    Results
  6. Schrödinger Reports Second Quarter 2025 Financial Results
    Results
  7. Schrödinger Reports Strong First Quarter 2025 Financial Results
    Results
  8. SUPREME COURT OF THE STATE OF NEW YORK
    News
  9. Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results
    Results
  10. Schrödinger Reports Third Quarter 2024 Financial Results
    Results
  11. Schrödinger Reports Strong Second Quarter 2024 Financial Results
    Results
  12. Schrödinger Reports First Quarter 2024 Financial Results
    Results
  13. Schrödinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results
    Results
  14. Schrödinger Reports Third Quarter 2023 Financial Results
    Results
  15. Schrödinger Reports Second Quarter 2023 Financial Results
    Results

See a number that looks wrong?